HIV/HBV合并感染相关肝癌切除术后预后差异:肝内Pre-S缺失突变与T细胞耗竭
该回顾性研究纳入143例接受根治性切除的HBV相关肝癌患者,比较HIV/HBV合并感染与HBV单一感染者的术后预后、HBV Pre-S缺失突变及免疫微环境。病毒学抑制患者经1:3倾向评分匹配后,合并感染组无复发生存(HR=4.03,95%CI 0.96-16.81,P=0.0058)和总生存(HR=12.04,95%CI 2.24-64.65,P<0.0001)均显著更差,肝内Pre-S缺失突变频率更高且CD4+、CD8+ T细胞浸润更低。
要点
- HIV/HBV合并感染肝癌切除术后预后较HBV单一感染更差。
- 合并感染肝组织Pre-S缺失突变频率更高且T细胞浸润减少。
- 病毒学抑制下仍需关注合并感染者的肝癌术后风险。
核心结论
- 病毒学抑制的HIV/HBV合并感染肝癌患者术后预后更差,肝内Pre-S缺失突变更多且T细胞耗竭更严重。
研究设计与样本
- 回顾性研究纳入143例接受根治性切除的HBV相关肝癌患者,病毒学抑制者按1:3倾向评分匹配。
主要发现
- 基线分析显示HIV/HBV-HCC组微血管侵犯率76.9% vs 40.0%(P=0.010),包膜侵犯率30.8% vs 8.5%(P=0.043)。
- 倾向评分匹配后,HIV/HBV-HCC组无复发生存更差(HR=4.03,95%CI 0.96-16.81,P=0.0058)。
- 倾向评分匹配后,HIV/HBV-HCC组总生存更差(HR=12.04,95%CI 2.24-64.65,P<0.0001)。
- HIV/HBV-HCC肝组织Pre-S准种缺失频率增加(P=0.003)。
- 肝内CD4+浸润降低(肿瘤P=0.01;癌旁P=0.007),CD8+在合并感染肿瘤中更低(P=0.039)。
临床怎么用
- 对HIV/HBV合并感染肝癌切除患者应加强术后随访和复发监测。
- 病毒学抑制不等于免疫微环境正常,需关注肝内T细胞耗竭状态。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 样本量有限,部分结果置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite effective antiretroviral use, the incidence of hepatocellular carcinoma (HCC) has not decreased in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfection. Our study compared postoperative prognosis, HBV Pre-S deletion, and immune microenvironment in coinfected and HBV-mono-infected individuals. METHODS: This retrospective study included 143 HBV-associated HCC patients who underwent curative resection. Virologically suppressed patients (HBV DNA < 1000 IU/mL and HIV RNA < 20 copies/mL) were matched by 1:3 propensity score matching (PSM). Hepatitis B virus Pre-S region was amplified by nested polymerase chain reaction (PCR) and sequenced. Tumor-infiltrating lymphocytes (CD3, CD4, CD8) were quantified by immunohistochemistry. Survival outcomes (recurrence-free survival [RFS] and overall survival [OS]) were analyzed using Kaplan-Meier curves. RESULTS: Baseline analysis showed higher rates of microvascular invasion (76.9% vs 40.0%, P = 0.010) and capsular invasion (30.8% vs 8.5%, P = 0.043) in the HIV/HBV-HCC group. After PSM, compared with HBV-HCC, HIV/HBV-HCC had a higher rate of RFS (hazard ratio [HR] = 4.03, 95% CI 0.96-16.81; P = 0.0058) and OS (HR = 12.04, 95% CI 2.24-64.65; P < 0.0001) was significantly worse. The HIV/HBV-HCC liver tissues showed an increased frequency of Pre-S quasispecies deletion (p = 0.003) and decreased intrahepatic CD4+ infiltration (tumor: P = 0.01; adjacent: P = 0.007). CD8+ expression was lower in coinfected tumors than in HBV-mono-infected tumors (P = 0.039). CONCLUSIONS: Virus-suppressed HIV/HBV-HCC showed a worse prognosis, with more Pre-S deletion mutants and more severe T-cell depletion observed in the liver, requiring further investigation of the mechanism.
引用
- Gao Q, Lan X, Yang F, et al. Prognostic Divergence in Human Immunodeficiency Virus/Hepatitis B Virus Versus Hepatitis B Virus-Associated Hepatocellular Carcinoma After Resection: Intrahepatic Pre-S Deletions Mutants and T-Cell Depletion Under Viral Suppression. J Infect Dis. 2025. PMID: 40811660. doi:10.1093/infdis/jiaf433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。